One‐year persistence of neutralizing anti‐SARS‐CoV‐2 antibodies in dialysis patients recovered from COVID‐19

The immunological mechanisms that modulate immune response to SARS‐CoV‐2 infection remain elusive. Little is known on the magnitude and the durability of antibody response against COVID‐19. There is consensus that patients with immune dysfunction, such as dialysis patients, may be unable to mount a robust and durable humoral immunity after infections. Recent studies showed that dialysis patients seroconverted after COVID‐19, but data on the durability of the immune response are missing. We reported the data of a durable anti‐spike protein seroconversion after natural SARS‐CoV‐2 infection in three patients on hemodialysis with a mean age of 67.2 ± 13.8 years. A mean antibody titer of 212.6 ± 174.9 UA/ml (Liaison®, DiaSorin) was found after one year (range, 366–374 days) from the diagnosis of COVID‐19. In conclusion, this case series provided evidence that patients receiving hemodialysis who recovered from severe COVID‐19 were able to mount a long‐lasting immune response against SARS‐CoV‐2. Although the protective capacity of this long‐term immunity remains to be determined, these patients did not report signs of reinfection after recovery from COVID‐19.